Markets:

Overview

News

Currencies

International

Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

1.970 -0.050 (-2.48%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher ↗

August 19, 2024

Via Benzinga

Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results ↗

August 19, 2024

Via Benzinga

Topics Stocks

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details ↗

August 19, 2024

Alzamend Neuro stock rises after partnering with Massachusetts General Hospital for a Phase 2 trial of AL001 to treat PTSD. The study aims to evaluate lithium's efficacy and safety in PTSD patients.

Via Benzinga

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

August 12, 2024

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Via News Direct

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

August 06, 2024

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

Via News Direct

ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024 ↗

December 18, 2023

Alzamend Neuro just reported results for the second quarter of 2024.

Via InvestorPlace

Headline

August 06, 2024

Headline

Via News Direct

EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study ↗

August 05, 2024

Alzamend Neuro is collaborating with Massachusetts General Hospital on a Phase 2 clinical trial of AL001 for Alzheimer's. This study aims to compare lithium levels in the brain between Alzheimer's...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 20, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 10, 2024

Via Benzinga

EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares ↗

May 09, 2024

Alzamend Neuro seals $500,000 Series A Convertible Preferred Stock deal with an investor. Plans to raise up to $25 million for clinical trials and working capital.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 08, 2024

Via Benzinga

Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide ↗

May 07, 2024

Alzemend Neuro made waves Tuesday when the company announced its decision to terminate its "at-the-market" equity offering program. Shares were down nearly 12% at last check.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 03, 2024

Via Benzinga

Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying ↗

April 24, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 16, 2024

Via Benzinga

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying ↗

April 04, 2024

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying ↗

April 02, 2024

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 27, 2024

Via Benzinga

ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024 ↗

March 26, 2024

ALZN stock results show that Alzamend Neuro missed analyst estimates for earnings per share the third quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 12, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 01, 2024

Via Benzinga

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying ↗

January 10, 2024

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 19, 2023

Via Benzinga

ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024 ↗

December 18, 2023

ALZN stock results show that Alzamend Neuro beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year ↗

December 11, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 30, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

Headline News about Alzamend Neuro, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today